Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile

• Published in: United European gastroenterology journal 2019-07, Vol.7 (6), p.807-814
• Main Authors: Gutin, Liat, Piceno, Yvette, Fadrosh, Douglas, Lynch, Kole, Zydek, Martin, Kassam, Zain, LaMere, Brandon, Terdiman, Jonathan, Ma, Averil, Somsouk, Ma, Lynch, Susan, El-Nachef, Najwa
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Crohn disease; Crohn Disease - etiology; Crohn Disease - therapy; dysbiosis; Fecal Microbiota Transplantation - adverse effects; Fecal Microbiota Transplantation - methods; fecal transplant; Female; Gastrointestinal Microbiome; Humans; inflammatory bowel disease; Male; Metagenomics - methods; microbiome; Middle Aged; Original; RNA, Ribosomal, 16S - genetics; Treatment Outcome; Young Adult
• ISSN: 2050-6406; 2050-6414
• DOI: 10.1177/2050640619845986

Background Emerging trials suggest fecal microbiota transplantation (FMT) is a promising treatment for ulcerative colitis; however, there is a paucity of data in Crohn disease (CD). Objective The objectives of this article are to determine whether single-dose FMT improves clinical and endoscopic outcomes in CD patients and to identify meaningful changes in the microbiome in response to FMT. Methods We performed a prospective, open-label, single-center study. Ten CD patients underwent FMT and were evaluated for clinical response (defined as decrease in Harvey-Bradshaw Index score ≥3 at one month post-FMT) and microbiome profile (16S ribosomal RNA sequencing) at one month post-FMT. Results Three of 10 patients responded to FMT. Two of 10 patients had significant adverse events requiring escalation of therapy. On microbiome analysis, bacterial communities of responders had increased relative abundance of bacteria commonly found in donor gut microbiota. Conclusions Single-dose FMT in this cohort of CD patients showed modest effect and potential for harm. Responders tended to have lower baseline alpha diversity, suggesting baseline perturbation of microbiota may be an indicator of potential responders to FMT in this patient population. Controlled trials are needed to further assess the efficacy and safety of FMT in CD and determine whether FMT is a viable option in this patient population. Clinicaltrials.gov number: NCT02460705.